Major contribution of Innova to the Sino-Innovax JV is in its' capacity for covid testing manufacture of both antigen and antibody rapid tests. Sinopharm has its own vaccine distribution network in China and Innova has through Biotime a testing distribution network in China and inroads to 20 or more primarily western nations buying covid tests..

Because Sinopharm has the 2021 goal of ramping to 7 billion dose production, a tight supply chain and anticounterfeiting are a necessity to ensure quality and security control of the product. Anticounterfeiting is needed on both vaccine dose and packaging and tests individually and packaging.

Part of the Pasaca agreement is/was that Pasaca would introduce QMC to potential clients and be compensated for that service. Sinopharm is the world's sixth largest vaccine manufacturer. That would be a great place to start.